https://www.tandfonline.com/doi/full/10.1080/14712598.2020.1772747
Will the US$5 million onasemnogene abeparvosec treatment for spinal muscular atrophy represent ‘value for money’ for the NHS? A rapid inquiry into suggestions that it may be cost-effective
